Matt Abernethy, Director of Fate Therapeutics FATE, has filed 0 purchases and 19 sales on the open market. The latest trade was on 06/12.

MA

MA

Matt Abernethy

Director

Company

Fate Therapeutics FATE

First filing

23/02/02

Trades

60 trades

Buys / sales

0 / 19

12-month net buying

No record

Last trade

06/12

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/02/13	25/02/14	2,558 sh2 trades	$116.86avg.	$298,926.42	−6.7%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/02/10	25/02/12	980 sh	$118.27	$115,904.6	−2.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/01/31	25/02/04	1,283 sh	$152.87	$196,132.21	−3.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/08/13	24/08/15	14,100 sh	$150.38	$2,120,358	−30.9%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/07/16	24/07/18	900 sh	$150.04	$135,036	−2.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/05/14–24/05/15	24/05/16	30,000 sh2 trades	$137.95avg.	$4,138,500	−48.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/02/13	24/02/15	1,352 sh	$132.85	$179,613.2	−4.1%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/02/06–24/02/08	24/02/08	2,260 sh2 trades	$138.73avg.	$313,529	−6.9%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/01/31	24/02/02	1,283 sh	$140.72	$180,543.76	−4.3%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/08/21	23/08/23	2,132 sh	$107.39	$228,955.48	−7.3%
Neurocrine BiosciencesNBIX	Open-market sale	23/02/06–23/02/08	23/02/08	28,588 sh5 trades	$102.61avg.	$2,933,465.04	−53.1%
Neurocrine BiosciencesNBIX	Open-market sale	23/01/31	23/02/02	1,283 sh	$109.98	$141,104.34	−5.7%